Gene editing is a type of genetic engineering and it is a relatively newer concept. It involves insertion, deletion, modification or replacement of DNA in a living organism’s genome. Gene editing could be a powerful tool for helping people suffering from chronic ailments. Some companies are working tirelessly to employ gene editing for solving health problems and Cambridge, Massachusetts based Verve Therapeutics is one of them. The company has now secured €56M in Series A2 to advance gene-editing therapies for reducing the risk of coronary heart disease.
Series A2 brings in €56M for research and development
The latest series A2 round for Verve Therapeutics was led by company’s existing investor GV, which was formerly known as Google Ventures. Furthermore, current investors ARCH Venture Partners, F-Prime Capital, and Biomatics Capital also joined the investment round. New investors Wellington Management and Casdin Capital also joined in. With the latest funding, the overall funds raised by the company touch a total of €109.5 million.